Toggle light / dark theme

Fujifilm stock rises as Japan considers Avigan for COVID-19 treatment

Avigan was developed as a flu medicine and also has been used for Ebola virus disease (EVD) treatment. EVD, which causes fatal hemorrhagic fever, resulted in more than 11,300 deaths in the West Africa region between 2014 and 2016. There is currently another outbreak in the Democratic Republic of Congo that has seen more than 2,000 fatalities to date.


HONG KONG – Fujifilm Holdings Corp. stock (TYO:4901) jumped 8.8% to ¥5,890 (US$53.48) on Feb. 25, as Japan considers using Avigan (favipiravir), an anti-influenza medication developed by the company’s Toyama Chemical Co. Ltd., to treat COVID-19. The share price ended the day at ¥5,567, for a gain of 2.83%.

The medication attracted market attention when Minister of Health, Labor and Welfare Katsunobu Kato said on Feb. 22 that the country is planning to test Avigan against COVID-19. “We hear from foreign countries that some drugs among those that have been used against influenza may be useful,” Kato said.

As of Feb. 25, more than 850 cases have been confirmed in Japan.

Genome Sequencing for Healthy People: Is it Time?

Would you want to know if you’re at risk of Alzheimer’s disease, for example?


The integration of sequencing into health care doesn’t fit very well in the model of how medicine is practiced today, but is well aligned with the future vision of health care that so many of us have — a vision that focuses upon prediction and prevention.

We imagine that personal genome sequencing could play a central role in bringing about a more personalized and participatory form of medicine — including a health care system where patients have more knowledge of their own risks and diagnoses and are empowered to act upon that information.

With that in mind, more of us are asking this question: Rather than focusing only on people with a suspected or diagnosed genetic disease, why not also use genome sequencing to help seemingly healthy people screen for all sorts of conditions, even diseases for which they have no known family history?

The first coronavirus vaccine could be in ‘clinical use’ in April

China has said that some vaccines for the novel coronavirus could be in clinical use next month as the number of global coronavirus cases soared past 100,000.

The country’s scientists are striving to develop immunisation products with five technologies simultaneously, according to officials.

‘We estimate that in April — in line with country’s relevant law and regulations – there is hope that some of the vaccines can enter the stage of clinical or emergency use,’ said Zheng Zhongwei, director of the Technical Development and Research Centre of China’s National Health Commission.

Human gene editing is too transformative to be guided by the few

My editorial from today’s (3/18/19) Financial Times:

Far sooner than most people realise, the genetics revolution will transform the world within and around us. Although we think about genetic technologies primarily in the context of healthcare, these tools are set to change the way we make babies, the nature of the babies we make and, ultimately, our evolutionary trajectory as a species — and we are not remotely ready for what’s coming. Yet we must be, to optimise the benefits and minimise the potential harms of genetic technologies.

Scientists are now able to manipulate biology to a previously unimaginable degree. In the past year, we’ve seen two female mice having their own babies, dramatic increases in the precision of gene-editing tools, and the birth in China of the first gene-edited humans. As this science advances exponentially, however, the regulations guiding how it should best be used are struggling to keep up. If the applications race forward without appropriate guard rails, the danger increases that more scientists like He Jiankui, the Chinese biophysicist who genetically altered two girls, will put people’s health at risk. But if the regulations are hastily written before the issues are clear, are too strong or are not flexible enough, many people who would otherwise have benefited from applied genetic technologies will be condemned to unnecessary suffering or even death.

Study suggests our brains use distinct firing patterns to store and replay memories

In a study of epilepsy patients, researchers at the National Institutes of Health monitored the electrical activity of thousands of individual brain cells, called neurons, as patients took memory tests. They found that the firing patterns of the cells that occurred when patients learned a word pair were replayed fractions of a second before they successfully remembered the pair. The study was part of an NIH Clinical Center trial for patients with drug-resistant epilepsy whose seizures cannot be controlled with drugs.

“Memory plays a crucial role in our lives. Just as are recorded as grooves on a record, it appears that our brains store memories in that can be replayed over and over again,” said Kareem Zaghloul, M.D., Ph.D., a neurosurgeon-researcher at the NIH’s National Institute of Neurological Disorders and Stroke (NINDS) and senior author of the study published in Science.

Dr. Zaghloul’s team has been recording electrical currents of drug-resistant epilepsy patients temporarily living with surgically implanted electrodes designed to monitor in the hopes of identifying the source of a patient’s seizures. This period also provides an opportunity to study neural activity during memory. In this study, his team examined the activity used to store memories of our past experiences, which scientists call episodic memories.

The Hunt for a Better Gut Bacteria in Central Africa

Powerful antibiotics and widespread sanitation practices have expanded lifespans across the industrialized world. But they have also come at a cost. Our microbiomes, or the trillions of microbes collectively working in our bodies to help regulate our immune system and food digestion, have lost much of its health-promoting bacteria because of our modern lifestyles and sanitation practices.

Scientists across the world are now looking to the planet’s few remaining pre-industrialized societies to see what industrialized guts have lost–and in doing so, could fundamentally change the way scientists think about germs. Thomas Morton heads to the Central African Republic to see this emerging field of microbiome science.

Check out VICE News for more: http://vicenews.com
Follow VICE News here:
Facebook: https://www.facebook.com/vicenews
Twitter: https://twitter.com/vicenews
Tumblr: http://vicenews.tumblr.com/
Instagram: http://instagram.com/vicenews
More videos from the VICE network: https://www.fb.com/vicevideo
#VICEonHBO

In World First, CRISPR Used on Patient’s Eye in Attempt to Cure Genetic Blindness

For the first time, doctors have attempted to cure blindness by gene-hacking a patient with CRISPR technology.

A team from Oregon Health & Science Institute injected three droplets of fluid that delivered the CRISPR DNA fragments directly into a patient’s eyeball, The Associated Press reports, in hopes that it will reverse a rare genetic condition called Leber congenital amaurosis, which causes blindness early in childhood.

“We literally have the potential to take people who are essentially blind and make them see,” Charles Albright, chief scientific officer of Editas Medicine, told the AP.

WHO says coronavirus death rate is 3.4% globally, higher than previously thought

World health officials said Tuesday the mortality rate for COVID-19 is 3.4% globally, higher than previous estimates of about 2%.

“Globally, about 3.4% of reported COVID-19 cases have died,” WHO Director-General Tedros Adhanom Ghebreyesus said during a press briefing at the agency’s headquarters in Geneva. In comparison, seasonal flu generally kills far fewer than 1% of those infected, he said.

CRISPR Scientists Hack Patient’s Genes in Bid to Cure Blindness

For the first time, doctors have attempted to cure blindness by gene-hacking a patient with CRISPR technology.

A team from Oregon Health & Science Institute injected three droplets of fluid that delivered the CRISPR DNA fragments directly into a patient’s eyeball, The Associated Press reports, in hopes that it will reverse a rare genetic condition called Leber congenital amaurosis, which causes blindness early in childhood.

“We literally have the potential to take people who are essentially blind and make them see,” Charles Albright, chief scientific officer of Editas Medicine, told the AP. Editas is one of the biotech companies that actually developed the treatment. “We think it could open up a whole new set of medicines to go in and change your DNA.”

/* */